Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
More News related to KERX
- Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
- Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
- Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
- Punk Ziegel Downgrades Keryx Biopharmaceuticals (KERX) to Accumulate
- BofA Downgrades Keryx Biopharmaceuticals (KERX) to Neutral
More News related to Press Releases
- CLO Systems to Exhibit at CEDIA EXPO, September 4-7, 2008 at BOOTH #1089
- American Airlines Seeks Government Approval to Defer Launch of Chicago to Beijing Service
- Most Gulf Coast Structures Not Safer Today Than They Were Three Years Ago, IBHS Says
- Zapata Delivers Record Cash Flow in Q2
- Windswept Environmental Group Announces Mobilization to Louisiana for Hurricane Gustav
NEW YORK, June 24 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, is scheduled to present at the Jefferies & Co. Healthcare Conference being held in New York City.
Mr. Weiss' presentation will be webcast live on Thursday, June 26th at 2:30pm ET and will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.
ABOUT KERYX BIOPHARMACEUTICALS, INC.
Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, or ESRD. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. The Company also has an in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.
KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com
SOURCE Keryx Biopharmaceuticals, Inc.
Related Categories
Press ReleasesStocks Mentioned
-0.01Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
